Sodium-glucose co-transporter 2 (SGLT2) inhibitors substantially slow progression of chronic kidney disease and reduce risk of acute kidney injury, but their effects on kidney physiology are incompletely understood. This study sought to assess the effects of empagliflozin on a comprehensive set of urine tubular and glomerular biomarkers.